Answers are grounded in this paper and cite their sources.
Background: Neuroendocrine neoplasms (NENs) are heterogeneous tumors with increasing incidence and substantial clinical variability. Emerging evidence suggests that the gut microbiota may influence NEN biology through immune, metabolic, and tumor microenvironment interactions. However, the underlying mechanisms remain poorly understood Methods: This narrative review synthesizes evidence on microbiota alterations across NEN subtypes, integrating microbiome profiling, intratumoral microbiome studies, multi-omics analyses, and Mendelian randomization (MR) investigations exploring potential causal associations and mediating pathways. Results: Patients with NENs consistently exhibit gut microbial dysbiosis, although signatures vary by tumor site. Evidence of an intratumoral microbiome in NENs suggests that bacteria may be integrated into the tumor microenvironment, potentially influencing immune regulation and tumor behavior. Multi-omics studies further demonstrate systemic metabolic alterations, including dysregulated tryptophan metabolism, altered circulating organic acids, and increased microbial-derived uremic toxins associated with metastatic disease. Mendelian randomization analyses support potential bidirectional causal relationships between gut microbiota and gastroenteropancreatic NENs, with evidence of immune- and metabolite-mediated effects. Importantly, microbiota involvement appears heterogeneous across NENs subtypes, reflecting tissue-specific ecological and hormonal contexts. Chronic inflammation may further link dysbiosis and tumorigenesis, contributing to a shared pathogenic continuum. Conclusions: The gut microbiota is emerging as a potential area of interest in NEN biology, with possible links to interconnected microbial, metabolic, and immune pathways. Although the underlying mechanisms and causal relationships remain to be established, current evidence suggests potential interactions between the host–microbiome axis and tumor development and progression. Further studies are needed to clarify these relationships and assess the potential of microbiota-based biomarkers and therapeutic strategies in NENs.
No takes yet. Share an insight, caveat, or question.
Salvia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: